Recurrence of primary sclerosing cholangitis after liver transplantation - The Hungarian experience.

Published on Mar 1, 2014in Interventional Medicine and Applied Science
· DOI :10.1556/IMAS.6.2014.1.2
Fanni Gelley9
Estimated H-index: 9
(Semmelweis University),
Gergely Zádori12
Estimated H-index: 12
(Semmelweis University)
+ 7 AuthorsBalázs Nemes13
Estimated H-index: 13
(Semmelweis University)
Sources
Abstract
Abstract Introduction Recurrence of primary sclerosing cholangitis (rPSC) after liver transplantation (OLT) significantly affects longterm graft survival. We aimed to evaluate the incidence of rPSC and clinical data of these patients in Hungary. Patients and Methods We retrospectively analyzed data of 511 whole liver transplantations from 1995 to 2011. During the study period, 49 OLTs were performed in 43 adult patients with end-stage PSC (10%). Results Out of 49 OLT, 24 cases were excluded, rPSC was diagnosed in six patients (12%). Patients with rPSC had significantly higher mortality (p = 0.009) and graft loss (p = 0.009) in comparison to patients without recurrent disease. Younger recipient age, higher donor BMI was observed in the rPSC group. One patient was diagnosed with de novo IBD, the remaining five patients had worsening IBD activity in the posttransplant period. PreOLT colectomy was performed in 21% of the control and none of the rPSC group. PostOLT colectomy was performed in two rPSC patients ...
📖 Papers frequently viewed together
67 Citations
204 Citations
11 Citations
References10
Newest
#1Fanni Gelley (Semmelweis University)H-Index: 9
#2P. Miheller (Semmelweis University)H-Index: 1
Last. Balázs Nemes (Semmelweis University)H-Index: 13
view all 5 authors...
Primary sclerosing cholangitis (PSC) is a common cause for liver transplantation (OLT) in Europe. It is frequently associated with inflammatory bowel disease (IBD). PSC associated IBD often runs a quiescent course but becomes more aggressive after OLT in some patients. Our aim was to evaluate the activity of IBD in PSC patients before and after OLT in Hungary. We retrospectively analyzed data from 411 whole-liver transplantations from 1995 to 2010 that included 41 patients transplanted due to PS...
13 CitationsSource
#1Bjarte Fosby (Oslo University Hospital)H-Index: 10
#2Tom H. KarlsenH-Index: 67
Last. Espen Melum (University of Oslo)H-Index: 27
view all 3 authors...
Primary sclerosing cholangitis (PSC) is a chronic progressive inflammatory disease affecting the bile ducts, leading to fibrosis and eventually cirrhosis in most patients. Its etiology is unknown and so far no effective medical therapy is available. Liver transplantation (LTX) is the only curative treatment and at present PSC is the main indication for LTX in the Scandinavian countries. Close to half of the PSC patients experience one or more episodes of acute cellular rejection (ACR) following ...
94 CitationsSource
#1Tom H. Karlsen (Oslo University Hospital)H-Index: 67
#2Erik Schrumpf (Oslo University Hospital)H-Index: 62
Last. Kirsten Muri Boberg (Oslo University Hospital)H-Index: 67
view all 3 authors...
Abstract Early studies in primary sclerosing cholangitis (PSC) were concerned with disease characterization, and were followed by epidemiological studies of PSC and clinical subsets of PSC as well as a large number of treatment trials. Recently, the molecular pathogenesis and the practical handling of the patients have received increasing attention. In the present review we aim to give an update on the pathogenesis of PSC and cholangiocarcinoma in PSC, as well as to discuss the current opinion o...
97 CitationsSource
#1Edward B. Alabraba (University of Birmingham)H-Index: 6
#2Peter Nightingale (Wellcome Trust)H-Index: 55
Last. James Neuberger (University of Birmingham)H-Index: 103
view all 7 authors...
Previously, we have found that the absence of the colon after liver transplantation (LT) protects the patient from recurrent primary sclerosing cholangitis (rPSC). As our previous observation has not been confirmed in other series, we have reviewed our cohort of patients grafted for primary sclerosing cholangitis (PSC) with greater numbers and longer follow-up to reassess the rate, consequences, and risk factors for rPSC. We collected data on patients who underwent LT for PSC between January 198...
204 CitationsSource
#1Jeffrey Campsen (Anschutz Medical Campus)H-Index: 13
#2Michael A. Zimmerman (Anschutz Medical Campus)H-Index: 29
Last. Igal Kam (Anschutz Medical Campus)H-Index: 52
view all 7 authors...
Orthotopic liver transplantation (OLT) is the treatment of choice for patients with end-stage primary sclerosing cholangitis (PSC). This study sought to chronicle the natural history of PSC recurrence following OLT and identify clinical variables that may contribute to disease reemergence. From 1988 to 2006, 1102 OLTs were performed in 1032 adults at the University of Colorado Health Sciences Center. Of these, 130 patients (12.6%) with PSC received 146 allografts. Recurrence was defined by a cli...
130 CitationsSource
#1David H. Adams (University of Birmingham)H-Index: 206
#2Bertus EksteenH-Index: 34
Last. Stuart M. CurbishleyH-Index: 23
view all 3 authors...
The gut digests, absorbs and metabolises nutrients whilst also acting as a barrier to pathogens entering from the intestinal lumen. Not all intestinal microbes are harmful and the full development of the gut immune system is shaped by interactions with commensal bacteria in a complex interplay which allows responses to harmless bacteria and nutrients to be suppressed whilst developing protective immune response against pathogens(1;2). Most of these responses occur in the intestinal mucosa and un...
53 CitationsSource
#2Marcin NowakH-Index: 5
Last. Leszek PaczekH-Index: 27
view all 15 authors...
Abstract Background Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease that progresses to end-stage liver disease. There are several specific problems related to the posttransplantation period in these patients. The aim of this study was to analyze a single center experience with 17 orthotopic liver transplantations (OLT) due to PSC. Patients and Methods Seventeen patients were included (10 men, 7 women). Actuarial patient and graft survival rates and the incidence of recurren...
11 CitationsSource
#1Urmila Khettry (Tufts University)H-Index: 30
#2Andrew P. Keaveny (Lahey Hospital & Medical Center)H-Index: 23
Last. Fredric D. Gordon (Tufts University)H-Index: 30
view all 8 authors...
Abstract The course and outcome of patients after liver transplantation (LT) for primary sclerosing cholangitis (PSC) are still debated. Our purpose is to define retrospectively, the post-LT clinicopathologic findings seen in 51 PSC patients with a follow-up of 2 to 14 years. Of the total 51 patients, 16 with native liver hilar xanthogranulomatous cholangiopathy (XGC) had median graft and patient survival of 573 and 835 days, respectively compared with 2489 and 2794 days, respectively, in 35 pat...
95 CitationsSource
#1Alonso Vera (Queen Elizabeth Hospital Birmingham)H-Index: 4
#2Shazma Moledina (Queen Elizabeth Hospital Birmingham)H-Index: 1
Last. James Neuberger (Queen Elizabeth Hospital Birmingham)H-Index: 103
view all 7 authors...
Summary Primary sclerosing cholangitis (PSC) is a disease of unknown cause that effects the biliary tree and is closely associated with inflammatory bowel disease. We did a retrospective analysis of the risk factors associated with recurrence of PSC in an allograft after liver transplantation. Recurrence of disease, assessed by liver histology or imaging the biliary tree, occurred in 56 of 152 patients (37%) at a median of 36 months (range 1·4–120 months). Multivariate analysis showed that being...
176 CitationsSource
#1Ivo W. Graziadei (Mayo Clinic)H-Index: 6
#2Russell H. Wiesner (Mayo Clinic)H-Index: 133
Last. Ruud A.F. Krom (Mayo Clinic)H-Index: 76
view all 13 authors...
Recurrence of primary sclerosing cholangitis (PSC) following liver transplantation has been suggested; however, it has not been fully defined because of numerous complicating factors and the lack of diagnostic criteria. In the present study, we investigated the recurrence of PSC by developing strict criteria and applying them to a large cohort of PSC patients who underwent liver transplantation. Between March 1985 and June 1996, 150 PSC patients underwent liver transplantation at the Mayo Clinic...
267 CitationsSource
Cited By11
Newest
#1Gerhard Rogler (UZH: University of Zurich)H-Index: 89
#2Abha G. Singh (UCSD: University of California, San Diego)H-Index: 11
Last. David T. Rubin (U of C: University of Chicago)H-Index: 91
view all 4 authors...
Inflammatory bowel diseases (IBDs) are systemic diseases that manifest not only in the gut and gastrointestinal tract, but also in the extraintestinal organs in many patients. The quality of life for patients with IBD can be substantially affected by these extraintestinal manifestations (EIMs). It is important to have knowledge of the prevalence, pathophysiology, and clinical presentation of EIMs in order to adapt therapeutic options to cover all aspects of IBD. EIMs can occur in up to 24% of pa...
Source
#1Palak J. TrivediH-Index: 25
#2Gideon M. Hirschfield (U of T: University of Toronto)H-Index: 69
Autoimmune liver diseases are chronic inflammatory hepatobiliary disorders that when classically defined encompass three distinctive clinical presentations; primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH). Meaningful changes in disease epidemiology are reported, with increasing incidence and prevalence of AIH and PSC in Europe, and rising prevalence of PBC across Europe, North America and the Asia-Pacific region. However, there appears to be...
1 CitationsSource
Last. Alan BonderH-Index: 13
view all 5 authors...
Autoimmune liver diseases are characterized by immune-mediated inflammation and eventual destruction of the hepatocytes and the biliary epithelial cells. They can progress to irreversible liver damage requiring liver transplantation. The post-liver transplant goals of treatment include improving the recipient’s survival, preventing liver graft-failure, and decreasing the recurrence of the disease. The keystone in post-liver transplant management for autoimmune liver diseases relies on identifyin...
Source
#1Tej I Mehta (USD: University of South Dakota)H-Index: 3
#2Simcha WeissmanH-Index: 4
Last. James H. Tabibian (UCLA: University of California, Los Angeles)H-Index: 14
view all 4 authors...
Primary sclerosing cholangitis (PSC) is a chronic, progressive, hepatobiliary disease characterized by inflammation and fibrosis of the intra- and extra-hepatic bile ducts. Its natural history is one that generally progresses towards cirrhosis, liver failure, cholangiocarcinoma, and ultimately disease-related death, with a median liver transplantation-free survival time of approximately 15-20 years. However, despite its lethal nature, PSC remains a heterogenous disease with significant variabili...
1 CitationsSource
#1Atsushi Tanaka (Teikyo University)H-Index: 33
#2Hajime Kono (Teikyo University)H-Index: 18
Last. M. Eric Gershwin (UC Davis: University of California, Davis)H-Index: 139
view all 4 authors...
Abstract Disease recurrence after organ transplantation associated with graft failure is a major clinical challenge in autoimmune diseases. Primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and autoimmune Hepatitis (AIH) are the three most common (autoimmune liver diseases) ALD for which liver transplantation (LT) is the most effective treatment option for patients with end-stage diseases. Although the 5- and 10-year survival rates of post-LT patients are remarkable (80–84%...
2 CitationsSource
#1Iris C. Steenstraten (LEI: Leiden University)H-Index: 1
#3Palak J. TrivediH-Index: 25
Last. P. W. Jeroen Maljaars (LEI: Leiden University)H-Index: 7
view all 7 authors...
BACKGROUND After liver transplantation primary sclerosing cholangitis (PSC), the condition returns in the transplanted liver in a subset of patients (recurrent primary sclerosing cholangitis, rPSC). AIM To define risk factors for rPSC. METHODS We searched Pubmed, Embase, Web of Science, and Cochrane library for articles published until March 2018. Studies addressing risk factors for developing rPSC were eligible for inclusion. A random effects meta-analysis was conducted using hazard ratios (HR)...
21 CitationsSource
#1Bettina M Buchholz (Royal Free Hospital)H-Index: 1
#2Panagis M. Lykoudis (Royal Free Hospital)H-Index: 10
Last. Giuseppe Fusai (Royal Free Hospital)H-Index: 30
view all 5 authors...
Role of colectomy in preventing recurrent primary sclerosing cholangitis in liver transplant recipients
17 CitationsSource
#1Bandar Al-JudaibiH-Index: 11
Last. Mansour Alghanem (UWO: University of Western Ontario)
view all 7 authors...
Background: The outcome of primary sclerosing cholangitis (PSC) after liver transplantation can be affected by recurrent PSC (rPSC) and subsequent graft failure. IgG4-related sclerosing disease is a recently described entity that has a similar morphological appearance to PSC, making the distinction difficult. However, IgG4-related sclerosing cholangitis has an excellent prognosis since it is steroid sensitive, but the impact of IgG4 on rPSC after liver transplant is still unknown. Objectives: To...
Source
#1Jacqueline B. Henson (Duke University)H-Index: 6
#2Yuval A. Patel (Duke University)H-Index: 9
Last. Andrew J. Muir (Duke University)H-Index: 63
view all 7 authors...
Background There is increasing evidence for a heterogeneity of phenotypes in primary sclerosing cholangitis (PSC), but differences across the age spectrum in adults with PSC have not been well characterized.
5 CitationsSource
#1Catherine Edmunds (Yale University)H-Index: 1
#2Udeme D. EkongH-Index: 16
Autoimmune liver diseases (AILD) are rare diseases with a reported prevalence of less than 50 per 100 000 population. As the research landscape and our understanding of AILDs and liver transplantation evolves, there remain areas of unmet needs. One of these areas of unmet needs is prevention of disease recurrence after liver transplantation. Disease recurrence is not an insignificant event because allograft loss with the need for retransplantation can occur. Patients transplanted for AILD are mo...
25 CitationsSource